Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant Discusses Strategy, Reflects On Four Years Of Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

True to form, the contrarian CEO of Valeant tells analysts that his company favors investment in business development over share buybacks, out-of-the spotlight emerging markets (Southeast Asia, South Africa, and Eastern and Central Europe), and niche therapeutic areas like dermatology and ophthalmology, all largely cash markets, where Valeant can stress its brand and distribution capabilities over scientific innovation.

You may also be interested in...

Business News, In Brief

Novo Nordisk and Allergan both report setbacks during their respective first quarter earnings calls. Meanwhile, Valeant and Actavis avoid speculation about a potential merger, and other Q1 happenings.

Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis

The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.

Valeant Readies For More Expansion In 2011

The specialty pharma is gearing up for as many as four more "tuck-in" acquisitions after completing a reverse-merger with Biovail and acquiring PharmaSwiss.


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts